Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Dementia is a condition that causes cognitive decline beyond normal ageing. Anxiety and depression are very common in people with dementia, but their needs are often under-recognised and under-served. Acceptance and Commitment Therapy (ACT) can reduce anxiety and depression by increasing psychological flexibility, the ability to pursue a meaningful life, in spite of unpleasant thoughts or feelings. There is much to learn about if and how ACT works for people with dementia, and whether it could be an effective psychological therapy for this population. Three participants with a dementia diagnosis and clinically-significant levels of anxiety and/or depression will be identified by their GP or Memory Assessment Service (MAS) in Nottinghamshire. Participants will attend 12 weekly, 90-minute sessions of ACT with the Principal Investigator (PI), accompanied by their caregiver if they so wish. In session, participants will complete several short questionnaires to measure their anxiety and depression, goals for therapy, psychological flexibility and relationship with the therapist. One week after the final session, an independent researcher will meet with participants and their carers to discuss their opinions of therapy and any changes to their anxiety and/or depression. One and three months after therapy, participants will be sent two short questionnaires to measure their current anxiety and depression. Information gathered from the independent researcher and questionnaires will be used to develop a case record for each participant, which will be looked at by independent psychotherapy experts to see whether ACT was effective. This research is being funded by Health Education England and is expected to last one year in total. Participant duration will last about 7 months. The study will form a Doctoral Thesis at the University of Nottingham and will be submitted to a peer-reviewed journal for distribution.
Description: Generalised anxiety disorder questionnaire (GAD-7), scored 0-21, where higher scores indicate a greater severity of anxiety.
Measure: Change in anxiety Time: Through study completion, up to 24 weeksDescription: Patient health questionnaire (PHQ-9), scored 0-27, where higher scores indicate a greater severity of depression.
Measure: Change in depression Time: Through study completion, up to 24 weeksDescription: Comprehensive assessment of Acceptance & Commitment Therapy (CompACT-SF), scored 0-48, where higher scores indicate increased psychological flexibility.
Measure: Change in psychological flexibility Time: Through study completion, up to 24 weeksDescription: Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWS), scored 7-35, where higher scores indicate higher mental wellbeing.
Measure: Change in wellbeing Time: Through study completion, up to 24 weeksDescription: Personal questionnaire (PQ), where higher scores indicate greater severity of problems.
Measure: Change in client problems Time: Through study completion, up to 24 weeksDescription: Session rating scale (SRS), does not involve numerical values but asks clients to mark on a line nearest to the description that best fits their experience (marks further towards the right indicate better therapeutic alliance).
Measure: Change in therapeutic alliance Time: Through study completion, up to 12 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports